ArticleMolecules (Basel, Switzerland)2025
A Biopolymeric Dextran-Chitosan Delivery System for Controlled Release of Antioxidant and Anti-Inflammatory Compounds: Lignin and Curcumin.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Topical strategies for antimicrobial delivery of peptide medicines for the management of chronic wounds.Discover nano · 2026Review
- Dextran-based stimuli-responsive hydrogels for smart dressings in wound healing.Journal of materials science. Materials in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biopolymeric drug delivery systems enhance the bioavailability and therapeutic efficacy of poorly soluble bioactive compounds. In this study, chitosan (Chi), dextran (Dex), carboxymethyl dextran (mDex), lignin (L), and curcumin (Cu) were combined to develop materials with controlled release, antioxidant, and anti-inflammatory properties. The mechanical evaluation showed that Chi-mDex-L-Cu exhibited the highest diametral tensile strength (2.40 MPa), a 1233% increase compared to Chi-mDex-L, due to strong hydrogen bonding interactions between curcumin and matrix components. Curcumin release kinetics, modeled using the Weibull equation, demonstrated that Chi-mDex-L-Cu presented the slowest release rate, reducing the cumulative release by 55.66% as compared to Chi-L-Cu, ensuring prolonged bioactivity. Despite its controlled release, Chi-mDex-L-Cu retained 60% antioxidant and 70% anti-inflammatory activity, making it a promising sustained-release system. The biocompatibility assessment confirmed cell viability above 85%, with Chi-mDex-L-Cu showing a slight (~10%) reduction at higher concentrations while remaining non-cytotoxic. These findings suggest that Chi-mDex-L-Cu is a strong candidate for biomedical applications requiring prolonged therapeutic effects, such as osteoarthritis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.